The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
IL-33/ST2 Axis in Organ Fibrosis
Open accessAbstract
Interleukin 33 (IL-33) is highly expressed in barrier sites, acting via the suppression of tumorigenicity 2 receptor (ST2). IL-33/ST2 axis has long been known to play a pivotal role in immunity and cell homeostasis by promoting wound healing and tissue repair. However, it is also involved in the loss of balance between extensive inflammation and tissue regeneration lead to remodeling, the hallmark of fibrosis. The aim of the current review is to critically evaluate the available evidence regarding the role of the IL-33/ST2 axis in organ fibrosis. The role of the axis in tissue remodeling is better understood considering its crucial role reported in organ development and regeneration. Generally, the IL-33/ST2 signaling pathway has mainly anti-inflammatory/anti-proliferative effects; however, chronic tissue injury is responsible for pro-fibrogenetic responses. Regarding pulmonary fibrosis mature IL-33 enhances pro-fibrogenic type 2 cytokine production in an ST2- and macrophage-dependent manner, while full-length IL-33 is also implicated in the pulmonary fibrotic process in an ST2-independent, Th2-independent fashion. In liver fibrosis, evidence indicate that when acute and massive liver damage occurs, the release of IL-33 might act as an activator of tissue-protective mechanisms, while in cases of chronic injury IL-33 plays the role of a hepatic fibrotic factor. IL-33 signaling has also been involved in the pathogenesis of acute and chronic pancreatitis. Moreover, IL-33 could be used as an early marker for ulcer-associated activated fibroblasts and myofibroblast trans-differentiation; thus one cannot rule out its potential role in inflammatory bowel disease-associated fibrosis. Similarly, the upregulation of the IL-33/ST2 axismay contribute to tubular cell injury and fibrosis via epithelial to mesenchymal transition (EMT) of various cell types in the kidneys. Of note, IL-33 exerts a cardioprotective role via ST2 signaling, while soluble ST2 has been demonstrated as a marker of myocardial fibrosis. Finally, IL-33 is a crucial cytokine in skin pathology responsible for abnormal fibroblast proliferation, leukocyte infiltration and morphologic differentiation of human endothelial cells. Overall, emerging data support a novel contribution of the IL-33/ST2 pathway in tissue fibrosis and highlight the significant role of the Th2 pattern of immune response in the pathophysiology of organ fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Inflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319
Moussion, C., Ortega, N., & Girard, J.-P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003331 · Cited by 1,179
Interleukin-33-Dependent Innate Lymphoid Cells Mediate Hepatic Fibrosis
Mchedlidze, T., Waldner, M., Zopf, S., Walker, J., Rankin, A. L., Schuchmann, M., Voehringer, D., McKenzie, A. N. J., Neurath, M. F., Pflanz, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.018 · Cited by 502
The mucosal immune system: master regulator of bidirectional gut-brain communications
Powell, N., Walker, M. M., & Talley, N. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.191 · Cited by 379
Interleukin-33 overexpression is associated with liver fibrosis in mice and humans
Marvie, P., Lisbonne, M., L’Helgoualc’h, A., Rauch, M., Turlin, B., Preisser, L., Bourd‐Boittin, K., Théret, N., Gascan, H., Piquet‐Pellorce, C., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00801.x · Cited by 251
Biliary repair and carcinogenesis are mediated by IL-33–dependent cholangiocyte proliferation
Li, J., Razumilava, N., Gores, G. J., Walters, S., Mizuochi, T., Mourya, R., Bessho, K., Wang, Y.-H., Glaser, S. S., Shivakumar, P., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73742 · Cited by 202
Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis
MacDonald, K. G., Dawson, N. A. J., Huang, Q., Dunne, J. V., Levings, M. K., & Broady, R. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1932 · Cited by 170
Cited by
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
“IL-33, another member of the IL-1 family of cytokines has been implicated in the regulation of fibrosis in several different organs.(175) In”
BackgroundDeciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis
Marcelin, G., Silveira, A. L. M., Martins, L. B., Ferreira, A. V. M., & Clément, K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129192 · Cited by 275
Revisiting fibrosis in inflammatory bowel disease: the gut thickens
D’Alessio, S., Ungaro, F., Noviello, D., Lovisa, S., Peyrin-Biroulet, L., & Danese, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00543-0 · Cited by 253
Metadata
- Authors
- Kotsiou, O. S., Gourgoulianis, K. I., & Zarogiannis, S. G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-10-24
- Volume
- 9
- Pages
- 2432-2432
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2898545691
- Cited by
- 232
- References
- 8
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.